drugset / Trial / NCT07116239

Edoxaban Steady-State PK/PD in Adults With Nephrotic Syndrome

NCT07116239

Non-randomizedParallel-groupOpen-labelPrevention

Summary

A study to evaluate the impact of nephrotic syndrome on the steady state pharmacokinetics and pharmacodynamics of edoxaban compared to health volunteers, and whether edoxaban can provide an equivalent anticoagulant effect to enoxaparin sodium.

Timeline

Start
2025-09
Primary completion
2026-02
Completion
2026-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Edoxaban Small molecule 60 mg Oral
Comparator Enoxaparin sodium Other / unclassified 40 mg Subcutaneous

Indications